Cytokinetics (CYTK) Gross Margin (2025 - 2026)
Cytokinetics (CYTK) posted quarterly Gross Margin of 99.17% for Q1 2026, down 83.0% year-over-year from 583.37% in Q1 2025, and down 0.83% quarter-over-quarter from 100.0% in Q1 2025.
Cytokinetics (CYTK) Gross Margin (2025 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Gross Margin for 2 consecutive years, with 99.17% the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | 90.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90.46% |
| Mar 31, 2026 | 99.17% |
| Mar 31, 2025 | 100.00% |